Albumin (Human)

Drug Overview

In the highly specialized field of Nephrology, managing the delicate balance of fluid compartments is critical, particularly in the context of advanced liver-renal syndromes. Albumin (Human) is a naturally occurring protein that serves as a cornerstone Targeted Therapy within the Plasma Expanders drug class. Unlike crystalloids, albumin provides essential osmotic support that prevents the collapse of the circulatory system during acute renal and hepatic crises.

As a high-molecular-weight Biologic, human albumin is indispensable for managing patients with Hepatorenal Syndrome (HRS), where it acts to stabilize hemodynamics and ensure adequate blood flow to the kidneys.

• Generic Name: Albumin (Human)
• US Brand Names: Albuked®, Albutein®, Flexbumin®, Plasbumin®
• Drug Class: Plasma Expanders (Colloids)
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Fully FDA-approved for volume depletion, hypoalbuminemia, and as adjunctive therapy in hepatorenal syndrome and large-volume paracentesis.

What Is It and How Does It Work? (Mechanism of Action)

Albumin is the primary plasma protein, accounting for approximately 75–80% of the normal plasma colloid oncotic pressure. Its mechanism of action in nephrological care is multifaceted, functioning through distinct molecular and physiological pathways:

1. Maintenance of Colloid Oncotic Pressure (COP): At the molecular level, albumin is a large, negatively charged globular protein that remains largely confined to the intravascular space. According to Starling’s Law, it exerts an osmotic pull that retains water within the capillaries. This prevents the “leakage” of fluid into the interstitial spaces (edema), which is critical in preventing circulatory collapse in patients with cirrhosis and renal failure.
2. Volumetric Expansion and Renoprotection: In patients with Hepatorenal Syndrome, the circulatory system undergoes massive arterial vasodilation, primarily in the splanchnic (gut) bed. This results in “effective” hypovolemia—where there is enough blood, but it is in the wrong place. Albumin expands the effective circulating volume, increasing the preload to the heart and improving cardiac output.
3. Molecular Transport and Scavenging: Albumin possesses specific binding sites (Sudlow’s sites I and II) that allow it to carry various endogenous and exogenous substances, including bilirubin, fatty acids, and toxins. In renal pathology, its ability to scavenge reactive oxygen species (ROS) and bind proinflammatory cytokines acts as a Targeted Therapy to reduce systemic inflammation and oxidative stress, which are major drivers of acute kidney injury (AKI).
4. Synergy with Vasoconstrictors: When combined with Terlipressin, albumin ensures that as the vasoconstrictor narrows the dilated splanchnic vessels, there is sufficient oncotic “pull” to keep the redirected blood within the systemic and renal circulation.

FDA-Approved Clinical Indications

Primary Indication

• Hepatorenal Syndrome (HRS-AKI): Combined with terlipressin to maintain intravascular volume, support oncotic pressure, and reverse renal failure in patients with cirrhosis and ascites.

Other Approved Uses

• Large-Volume Paracentesis: Prevention of post-paracentesis circulatory dysfunction (PPCD) following the removal of >5 liters of ascitic fluid.
• Spontaneous Bacterial Peritonitis (SBP): Adjunctive treatment to reduce the incidence of renal failure and mortality.
• Shock and Acute Volume Depletion: Emergency restoration of cardiac output in hypovolemic shock.
• Hypoalbuminemia: Replacement therapy in severe protein-losing states such as nephrotic syndrome or acute liver failure.

Dosage and Administration Protocols

Dosing of Albumin in Nephrology is strictly governed by the clinical indication and the patient’s fluid status.

Dose Adjustments:

• Cardiac Failure: Extreme caution is required; infusion rates must be slowed to prevent pulmonary edema.
• Renal Insufficiency: While indicated for HRS, patients with chronic oliguric renal failure require careful monitoring for fluid overload.

Clinical Efficacy and Research Results

Recent clinical data (2020–2026), including the landmark CONFIRM trial, have reaffirmed the role of albumin in the “Terlipressin-Albumin” protocol:

• HRS Reversal: The combination of albumin and terlipressin achieves HRS reversal in approximately 30–35% of patients, significantly higher than albumin monotherapy.
• Survival Rates: Clinical studies indicate that patients receiving the full albumin protocol for SBP show a reduction in renal failure incidence from 30% down to 10%, with a corresponding improvement in 3-month survival.
• Hemodynamic Stabilization: Use of albumin during large-volume paracentesis reduces the incidence of post-procedural AKI by over 15%, as measured by serum creatinine stabilization and mean arterial pressure (MAP) maintenance.

Safety Profile and Side Effects

Black Box Warning: Currently, there is no FDA-mandated Black Box Warning for Albumin (Human). However, it is contraindicated in patients with severe anemia or heart failure with normal or increased intravascular volume.

Common Side Effects (>10%)

• Fluid Overload (Hypervolemia).
• Elevated blood pressure (Hypertension).
• Chills and fever (Febrile reactions).

Serious Adverse Events

• Pulmonary Edema: Sudden accumulation of fluid in the lungs due to excessive oncotic pull or rapid infusion.
• Anaphylaxis: Rare but severe allergic reactions to the protein components.
• Coagulopathy: Large volumes may dilute clotting factors, leading to increased bleeding risk.

Management Strategies

• Vigilance: Monitor Central Venous Pressure (CVP) or use non-invasive hemodynamic monitoring to prevent “over-filling.”
• Intervention: If signs of respiratory distress occur (crackles, decreased oxygen saturation), stop the infusion immediately and administer diuretics if appropriate.

Research Areas

While Albumin is a traditional Biologic, current research (2025-2026) is exploring its role as a “stabilizing niche” in regenerative medicine. In cellular therapies for liver and kidney repair, albumin is being studied as a carrier medium to enhance the survival of infused Mesenchymal Stem Cells (MSCs). Its antioxidant properties help shield these cells from the “cytokine storm” present in acute-on-chronic liver failure, theoretically improving the engraftment and paracrine signaling of regenerative treatments.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Baseline Electrolytes and Serum Creatinine.
• Baseline Serum Albumin and Liver Function Tests (LFTs).
• Assessment of fluid status (Physical exam, lung auscultation, or ultrasound).

Precautions During Treatment:

• Infusion Rate: Avoid rapid infusions; 5% solutions should generally not exceed 5–10 mL/min, and 25% solutions should be administered more slowly.
• Symptom Vigilance: Monitor for shortness of breath, cough, or jugular venous distention.

Do’s and Don’ts:

• DO ensure the solution is clear; discard if it appears turbid or contains sediment.
• DO monitor urine output closely as a sign of renal perfusion improvement.
• DON’T mix albumin with other medicinal products, including vancomycin or protein hydrolysates.
• DON’T use sterile water for injection to dilute albumin, as it can cause life-threatening hemolysis.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Albumin (Human) is a prescription biologic that must be administered under the supervision of a qualified physician, typically in a hospital setting. Always consult your healthcare provider for specific medical concerns.